Blood pressure drug recalls — an update on Valsartan | Society News | SupChina
Free

We're a new type of news publication

China news you won't read elsewhere.

Weekly Newsletter

Get a roundup of the most important and interesting stories coming out of China.

Podcasts

Sinica, TechBuzz China, and our 6 other shows are the undisputed champs of China podcasts. Listen now.

Feature Articles

Interactive, web-based deep dives into the real China.

Premium

Join the thousands of executives, diplomats, and journalists that rely on SupChina for daily analysis of the full China story.

Daily Newsletter

All the news, every day. Premium analysis directly from our Editor-in-Chief Jeremy Goldkorn.

24/7 Slack Community

Have China-related questions and want answers? Our Slack community is a place to learn, network, and opine.

Free Live Events & More

Monthly live conference calls with leading experts, free entry to SupChina live events in cities around the world, and more.

"A jewel in the crown of China reporting. I go to it, look for it daily. Why? It adds so much insight into the real China. Essential news, culture, color. I find SupChina superior."
— Max Baucus, former U.S. Ambassador to China

Free

We're a new type of news publication

China news you won't read elsewhere.

Weekly Newsletter

Get a roundup of the most important and interesting stories coming out of China.

Podcasts

Sinica, TechBuzz China, and our 6 other shows are the undisputed champs of China podcasts. Listen now.

Feature Articles

Interactive, web-based deep dives into the real China.

OR… for more in-depth analysis and an online community of China-focused professionals:

Learn About Premium Access Now!
Learn More
Minimize
Learn More
Minimize

Blood pressure drug recalls — an update on Valsartan

Part of the daily SupChina newsletter. Subscribe for free

In our Access members newsletter (paywall) yesterday, we covered the recalls of the blood pressure medicine Valsartan because of a carcinogen found in an ingredient produced by Chinese suppliers Zhejiang Huahai Pharmaceuticals, Tianyu Pharmaceutical, and Rundu Pharma.

If you take this medicine, the American FDA has updated its recall and also published a list of Valsartan products not currently recalled. If you are outside the United States, call the supplier, as the batch numbers are different and the FDA lists may not apply to your country.

The FDA is now saying that based on manufacturer records “of the recalled valsartan, some levels of the impurity may have been in the valsartan-containing products for as long as four years,” according to website Fierce Pharma. However, the risk to users of the affected batches is relatively slight:

FDA scientists estimate that if 8,000 people took the highest valsartan dose (320 mg) from the recalled batches every day for the full four years, there may be one additional case of cancer over the lifetimes of those 8,000 people.

In the Chinese media, the only news stories I can find about the recalls are about the share prices of the three affected Chinese companies — see, for example, the top results for a Baidu News search for 缬沙坦 (xié shā tǎn — Valsartan): every single result is a report on stock market reactions to the affair.

Jeremy Goldkorn

Jeremy Goldkorn worked in China for 20 years as an editor and entrepreneur. He is editor-in-chief of SupChina, and co-founder of the Sinica Podcast.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.